Oral dydrogesterone versus oral micronized progesterone: Interim analysis of a randomized controlled trial in pregnant women with threatened miscarriage

سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 27

فایل این مقاله در 12 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJRM-24-7_004

تاریخ نمایه سازی: 18 مهر 1405

چکیده مقاله:

Background: Progestogen/progestin supplementation is favorable in threatened miscarriage. However, comparative data on the efficacy, safety, and immunomodulatory functions of types/routes of administration are limited. Objective: This study compares oral dydrogesterone (DYD) vs. oral micronized progesterone (MP) in threatened miscarriage. Materials and Methods: This ongoing, investigator-initiated, randomized controlled trial includes eligible, consenting, pregnant women who had vaginal bleeding and/or abdominal pain during first trimester. Participants are treated up to ۱۴ gestational wk with DYD (۴۰ mg stat followed by ۱۰ mg thrice daily) or MP (۲۰۰ mg twice daily). The following outcomes till ۲۰ gestational wk are presented: miscarriage rate (primary); change in serum cytokines (interferon gamma [IFN-γ], tumor necrosis factor alpha [TNF-α], interleukin [IL]-۴, IL-۱۰), time to symptom resolution (secondary); treatment-emergent adverse events (AEs; safety). Results: Interim analysis includes ۱۱۶ participants (DYD, ۶۲; MP, ۵۴). Miscarriage rate in DYD (۱۴.۵۲%) was statistically comparable to, but numerically lower than, that in MP (۲۰.۳۷%; p = ۰.۵۵۸). The mean time to symptom resolution in DYD and MP was, respectively, ۶.۴۹ and ۷.۳۸ days for vaginal bleeding, and ۷.۱۵ and ۷.۶۷ days for abdominal pain. Numerically, IFN-γ and TNF-α decreased and IL-۴ increased with DYD, while IFN-γ decreased and IL-۴ and IL-۱۰ increased with MP. Considering Th۱:Th۲ ratio, numerical decreases in IFN-γ:IL-۴, IFN-γ:IL-۱۰, and TNF-α:IL-۴ were evident with DYD but not with MP. No AE was related to study medication. Conclusion: Compared to oral MP, oral DYD resulted in a numerically lower miscarriage rate and time to symptom resolution, concomitant to favorable decrease in Th۱:Th۲ ratio.

نویسندگان

Alka Kriplani

Department of Obstetrics and Gynecology, Paras Hospitals, Gurugram, Haryana, India.

Ashima Taneja

Department of Obstetrics and Gynecology, Dayanand Medical College & Hospital, Ludhiana, Punjab, India.

Gouri Shankar Kamilya

Department of Obstetrics and Gynecology, IPGME;R and SSKM Hospital, Kolkata, West Bengal, India.

Thirunavukkarasu Ramani Devi

Department of Obstetrics and Gynecology, Ramakrishna Medical Center LLP, Tiruchirappalli, Tamil Nadu, India.

Amol Pawar

Department of Obstetrics and Gynecology, Nowrosjee Wadia Maternity Hospital, Mumbai, Maharashtra, India.

Tanusree Gupta

Department of Gynecology and Obstetrics, Udyan Health Care Pvt. Ltd., Lucknow, Uttar Pradesh, India.

Gayathri Karthik Nagesh

Department of Obstetrics and Gynecology, Manipal Hospital, Bengaluru, Karnataka, India.

Shilpa Choudhary

Lifeline Medicare Hospital, Mumbai, Maharashtra, India.

Tapan Pattanaik

Department of Obstetrics and Gynecology, Sum Ultimate Medicare Hospital, Bhubaneswar, Odisha, India.

Monjori Mitra

Department of Pediatrics, Institute of Child Health, Kolkata, West Bengal, India.

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Devall AJ, Papadopoulou A, Podesek M, Haas DM, Price MJ, ...
  • Zhao H, He W, Yang Z. A pairwise and network ...
  • FOGSI. Management of women with threatened miscarriage: Role of medical ...
  • Wang X-X, Luo Q, Bai W-P. Efficacy of progesterone on ...
  • Zhao Y, D’Souza R, Gao Y, Hao Q, Kallas-Silva L, ...
  • Zhao H, He W, Xia C, Yang Z. Efficacy and ...
  • Raghupathy R, Szekeres-Bartho J. Progesterone: A unique hormone with immunomodulatory ...
  • Ibrahim Z, Said M, El Nahas K, Younes S, Ali ...
  • Kriplani A, Kamilya GS, Devi TR, Taneja A, Pawar A, ...
  • Siew JYS, Allen JC, Hui CYY, Ku CW, Malhotra R, ...
  • Lou C, Wang C, Zhao Q, Jin F. Effect of ...
  • Verma S, Yadav P. To study the comparison between oral ...
  • Shaikh R, Jalbani A, Lashari S, Sangi S-U-N, Brohi S, ...
  • Nagarkatti R, Mehra D, Mandal S, Dhawan A, Joshi P, ...
  • Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in ...
  • Kuptarak A, Phupong V. Oral dydrogesterone for prevention of miscarriage ...
  • Vuong LN, Pham TD, Le KT, Ly TT, Le HL, ...
  • Tournaye H, Sukhikh GT, Kahler E, Griesinger G. A phase ...
  • Jiang X, Li W, Chen X, Kuang Y, Jiang S. ...
  • Vidal A, Dhakal C, Werth N, Weiss JM, Lehnick D, ...
  • نمایش کامل مراجع